ANNGEEN

ANNGEEN is an innovative enterprise dedicated to high-throughput gene sequencing technology and providing comprehensive solutions for clinical medicine, with a focus on high-throughput sequencing clinical services. ANNGEEN is one of the first companies in China to implement the clinical application of gene sequencing technology. Based on high-throughput sequencing technology and advanced bioinformatics analysis, the company has comprehensively laid out its presence in the field of molecular diagnostics for genetic diseases. It aims to provide holistic solutions for genetic disease testing in clinical settings. Its product portfolio covers clinical testing services for hereditary cardiovascular diseases, kidney diseases, blood disorders, hereditary cancers, as well as personalized medication guidance testing and tumor molecular testing. Additionally, it engages in the development, production, and registration of in vitro diagnostic kits, striving to become a globally leading provider of full-process products and services for genetic disease testing. The company operates subsidiaries such as AnnCes (Beijing) Biotechnology Co., Ltd., ANNGEEN (Beijing) Biotechnology Co., Ltd., and Suzhou ANNGEEN Medical Laboratory Co., Ltd. ANNGEEN has established long-term and stable partnerships with many renowned medical institutions both domestically and internationally. It has set up LDT joint laboratories and independent medical testing facilities co-built with hospitals in more than 10 major cities across China. The core team consists of experts from fields such as cytogenetics, pathology, molecular biology, and bioinformatics analysis from both within and outside China.